Search Results - "Ellis, Peter M."

Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update by Hanna, Nasser, Johnson, David, Temin, Sarah, Baker, Jr, Sherman, Brahmer, Julie, Ellis, Peter M, Giaccone, Giuseppe, Hesketh, Paul J, Jaiyesimi, Ishmael, Leighl, Natasha B, Riely, Gregory J, Schiller, Joan H, Schneider, Bryan J, Smith, Thomas J, Tashbar, Joan, Biermann, William A, Masters, Gregory

“…Purpose Provide evidence-based recommendations updating the 2015 ASCO guideline on systemic therapy for patients with stage IV non-small-cell lung cancer…”
Get full text

Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update by Hanna, Nasser H, Schneider, Bryan J, Temin, Sarah, Baker, Jr, Sherman, Brahmer, Julie, Ellis, Peter M, Gaspar, Laurie E, Haddad, Rami Y, Hesketh, Paul J, Jain, Dharamvir, Jaiyesimi, Ishmael, Johnson, David H, Leighl, Natasha B, Phillips, Tanyanika, Riely, Gregory J, Robinson, Andrew G, Rosell, Rafael, Schiller, Joan H, Singh, Navneet, Spigel, David R, Stabler, Janis O, Tashbar, Joan, Masters, Gregory

“…The aim of this work is to provide evidence-based recommendations updating the 2017 ASCO guideline on systemic therapy for patients with stage IV…”
Get full text

Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non-Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update by Kris, Mark G, Gaspar, Laurie E, Chaft, Jamie E, Kennedy, Erin B, Azzoli, Christopher G, Ellis, Peter M, Lin, Steven H, Pass, Harvey I, Seth, Rahul, Shepherd, Frances A, Spigel, David R, Strawn, John R, Ung, Yee C, Weyant, Michael

“…Purpose The panel updated the American Society of Clinical Oncology (ASCO) adjuvant therapy guideline for resected non-small-cell lung cancers. Methods ASCO…”
Get full text

Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update by Masters, Gregory A, Temin, Sarah, Azzoli, Christopher G, Giaccone, Giuseppe, Baker, Jr, Sherman, Brahmer, Julie R, Ellis, Peter M, Gajra, Ajeet, Rackear, Nancy, Schiller, Joan H, Smith, Thomas J, Strawn, John R, Trent, David, Johnson, David H

“…To provide evidence-based recommendations to update the American Society of Clinical Oncology guideline on systemic therapy for stage IV non-small-cell lung…”
Get full text

Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline by Singh, Navneet, Temin, Sarah, Baker, Jr, Sherman, Blanchard, Elizabeth, Brahmer, Julie R, Celano, Paul, Duma, Narjust, Ellis, Peter M, Elkins, Ivy B, Haddad, Rami Y, Hesketh, Paul J, Jain, Dharamvir, Johnson, David H, Leighl, Natasha B, Mamdani, Hirva, Masters, Gregory, Moffitt, Pamela R, Phillips, Tanyanika, Riely, Gregory J, Robinson, Andrew G, Rosell, Rafael, Schiller, Joan H, Schneider, Bryan J, Spigel, David R, Jaiyesimi, Ishmael A

“…To provide evidence-based recommendations updating the 2020 ASCO and Ontario Health (Cancer Care Ontario) guideline on systemic therapy for patients with stage…”
Get full text

Postoperative Adjuvant Systemic Therapy in Completely Resected Non-Small Cell Lung Cancer: A Systematic Review by Bradbury, Penelope, MD, Sivajohanathan, Duvaraga, MPH, Chan, Adrien, MD, Kulkarni, Swati, MD, Ung, Yee, MD, Ellis, Peter M., MBBS, PhD

“…Abstract Purpose To determine whether the use of postoperative adjuvant systemic therapy in patients with completely resected non-small cell lung cancer…”
Get full text

Update on the Management of Stage III NSCLC: Navigating a Complex and Heterogeneous Stage of Disease by Sathiyapalan, Arani, Baloush, Ziad, Ellis, Peter M

“…Stage III nonsmall cell lung cancer (NSCLC) represents a heterogeneous group of patients. Many patients are treated with curative intent multimodality therapy,…”
Get full text

Immune Checkpoint Inhibitors for Patients with Advanced Non-Small Cell Lung Cancer: A Systematic Review by Ellis, Peter M., MBBS, PhD, Vella, Emily T., PhD, Ung, Yee C., MD

“…Abstract Introduction Second-line treatment options are limited for patients with advanced non-small cell lung cancer (NSCLC). Standard therapy includes…”
Get full text

Chemo-Immunotherapy in First Line Extensive Stage Small Cell Lung Cancer (ES-SCLC): A Systematic Review and Meta-Analysis by Sathiyapalan, Arani, Febbraro, Michela, Pond, Gregory R, Ellis, Peter M

“…Small cell lung cancer (SCLC) is an aggressive neuroendocrine carcinoma with early metastatic potential. The standard-of-care treatment has not changed in…”
Get full text

First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: a systematic review by Goffin, John, Lacchetti, Christina, Ellis, Peter M, Ung, Yee C, Evans, William K

“…Non-small cell lung cancer (NSCLC) frequently presents at an incurable stage, and a majority of patients will be considered for palliative chemotherapy at some…”
Get more information

Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial by Ellis, Peter M, Dr, Shepherd, Frances A, Prof, Millward, Michael, Prof, Perrone, Francesco, PhD, Seymour, Lesley, Prof, Liu, Geoffrey, MD, Sun, Sophie, MD, Cho, Byoung Chul, MD, Morabito, Alessandro, MD, Leighl, Natasha B, MD, Stockler, Martin R, Prof, Lee, Christopher W, MD, Wierzbicki, Rafal, MD, Cohen, Victor, MD, Blais, Normand, MSc, Sangha, Randeep S, MD, Favaretto, Adolfo G, MD, Kang, Jin Hyoung, MD, Tsao, Ming-Sound, Prof, Wilson, Carolyn F, MSc, Goldberg, Zelanna, MD, Ding, Keyue, PhD, Goss, Glenwood D, Prof, Bradbury, Penelope Ann, MBBCh

“…Summary Background Dacomitinib is an irreversible pan-HER tyrosine-kinase inhibitor with preclinical and clinical evidence of activity in non-small-cell lung…”
Get full text

Randomized, Double-Blind Trial of Carboplatin and Paclitaxel With Either Daily Oral Cediranib or Placebo in Advanced Non–Small-Cell Lung Cancer: NCIC Clinical Trials Group BR24 Study by GOSS, Glenwood D, ARNOLD, Andrew, ELLIS, Peter M, LAURIE, Scott A, DING, Keyue, FRYMIRE, Eliot, GAUTHIER, Isabelle, LEIGHL, Natasha B, HO, Cheryl, NOBLE, Jonathan, LEE, Christopher W, SEYMOUR, Lesley, SHEPHERD, Frances A, DEDIU, Mircea, CIULEANU, Tudor-Eliade, FENTON, David, ZUKIN, Mauro, WALDE, David, LABERGE, Francis, VINCENT, Mark D

“…PURPOSE This phase II/III double-blind study assessed efficacy and safety of cediranib with standard chemotherapy as initial therapy for advanced…”
Get full text

Biopsychosocial Associates of Psychological Distress and Post-Traumatic Growth among Canadian Cancer Patients during the COVID-19 Pandemic by Zhang, Karen M, Mukherjee, Som D, Pond, Gregory, Roque, Michelle I, Meyer, Ralph M, Sussman, Jonathan, Ellis, Peter M, Bryant-Lukosius, Denise

“…Understanding both the positive and negative psychological outcomes among cancer patients during the pandemic is critical for planning post-pandemic cancer…”
Get full text

Patterns of Relapse in Small Cell Lung Cancer: Competing Risks of Thoracic versus CNS Relapse by Ellis, Peter M., Swaminath, Anand, Pond, Gregory R.

“…Introduction: Treatment algorithms for small cell lung cancer (SCLC) are determined largely by the Veterans Affairs Lung Cancer Staging Group (VALCSG) staging…”
Get full text

Cancer Care Ontario and American Society of Clinical Oncology Adjuvant Chemotherapy and Adjuvant Radiation Therapy for Stages I-IIIA Resectable Non–Small-Cell Lung Cancer Guideline by PISTERS, Katherine M. W, EVANS, William K, GASPAR, Laurie E, PASS, Harvey I, SPIGEL, David R, STRAWN, John R, UNG, Yee C, SHEPHERD, Frances A, AZZOLI, Christopher G, KRIS, Mark G, SMITH, Christopher A, DESCH, Christopher E, SOMERFIELD, Mark R, BROUWERS, Melissa C, DARLING, Gail, ELLIS, Peter M

“…To determine the role of adjuvant chemotherapy and radiation therapy in patients with completely resected stage IA-IIIA non-small-cell lung cancer (NSCLC). The…”
Get full text

Implementation of Liquid Biopsy in Non-Small-Cell Lung Cancer: An Ontario Perspective by Breadner, Daniel, Hwang, David M, Husereau, Don, Cheema, Parneet, Doucette, Sarah, Ellis, Peter M, Kassam, Shaqil, Leighl, Natasha, Maziak, Donna E, Selvarajah, Shamini, Sheffield, Brandon S, Juergens, Rosalyn A

“…Lung cancer is the leading cause of cancer-related deaths in Canada, with non-small-cell lung cancer (NSCLC) accounting for the majority of cases. Timely…”
Get full text

Growth differentiation factor 15 (GDF15) predicts relapse free and overall survival in unresected locally advanced non-small cell lung cancer treated with chemoradiotherapy by Di Pastena, Fiorella, Pond, Gregory, Tsakiridis, Evangelia E, Gouveia, Andre, Ahmadi, Elham, Biziotis, Olga-Demetra, Ali, Amr, Swaminath, Anand, Okawara, Gordon, Ellis, Peter M, Abdulkarim, Bassam, Ahmed, Naseer, Robinson, Andrew, Roa, Wilson, Valdes, Mario, Kavsak, Peter, Wierzbicki, Marcin, Wright, James, Steinberg, Gregory, Tsakiridis, Theodoros

“…Introduction Growth differentiation factor 15 (GDF15) is a cytokine of the TGF[beta] family. Here, we analyzed GDF15 levels in patients with locally advanced…”
Get full text

Communicating With Realism and Hope: Incurable Cancer Patients' Views on the Disclosure of Prognosis by HAGERTY, Rebecca G, BUTOW, Phyllis N, ELLIS, Peter M, LOBB, Elizabeth A, PENDLEBURY, Susan C, LEIGHL, Natasha, MACLEAD, Craig, TATTERSALL, Martin H. N

“…To identify preferences for the process of prognostic discussion among patients with incurable metastatic cancer and variables associated with those…”
Get full text

Tumor Cavitation: Impact on Objective Response Evaluation in Trials of Angiogenesis Inhibitors in Non–Small-Cell Lung Cancer by CRABB, Simon J, PATSIOS, Demetris, LAURIE, Scott A, SAUERBREI, Eric, ELLIS, Peter M, ARNOLD, Andrew, GOSS, Glenwood, LEIGHL, Natasha B, SHEPHERD, Frances A, POWERS, Jean, SEYMOUR, Lesley

“…We have observed cavitation of lesions in clinical trials of an angiogenesis inhibitor combined with chemotherapy for non-small-cell lung cancer (NSCLC). We…”
Get full text

Pertuzumab Cardiotoxicity in Patients With HER2-Positive Cancer: A Systematic Review and Meta-analysis by Alhussein, Muhammad Mustafa, Mokbel, Abir, Cosman, Tammy, Aghel, Nazanin, Yang, Eric H., Mukherjee, Som D., Dent, Susan, Ellis, Peter M., Dhesy-Thind, Sukhbinder, Leong, Darryl P.

“…Human epidermal growth factor receptor 2 (HER2) overexpressing malignancies, including breast and gastro-esophageal, are associated with a poor prognosis. The…”
Get full text